Markets
ImmunityBio Stock Plunges 22% After Its Adjusted Quarterly Loss Widens
ANKTIVA product revenue grew 53%, while research spending rose and the company reported success in a bladder-cancer trial.
ImmunityBio (IBRX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
ANKTIVA product revenue grew 53%, while research spending rose and the company reported success in a bladder-cancer trial.
SEC Filings
Nine-month product sales reached $143.6 million, while the company plans to seek approval for patients not previously treated with BCG.
SEC Filings
The company targets an FDA application by year-end 2026 to reach patients receiving BCG for the first time.
SEC Filings
The company says it is the first FDA approval covering papillary-only tumors in BCG-unresponsive disease, resting on earlier data from carcinoma in situ patients.